Gts Securities LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Gts Securities LLC

  • $46.5 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$4.13 - $6.79 $101,185 - $166,355
-24,500 Reduced 25.28%
72,400 $447,000
Q1 2024

May 15, 2024
SELL
$4.89 - $7.65 $23,961 - $37,485
-4,900 Reduced 4.81%
96,900 $492,000
Q4 2023

Feb 14, 2024
SELL
$4.98 - $6.77 $46,812 - $63,637
-9,400 Reduced 8.45%
101,800 $609,000
Q3 2023

Nov 15, 2023
BUY
$6.71 - $7.92 $746,152 - $880,704
111,200 New
111,200 $787,000

Others Institutions Holding BCRX

# of Institutions
257
Shares Held
173M
Call Options Held
397K
Put Options Held
444K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.47B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email